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Background: Adherence to an antiretroviral regimen is imperative for treatment success in both HIV infected adults
and children. Likewise, adherence to antiretroviral prophylaxis is critical in HIV prevention. Studies on pediatric
adherence are limited, particularly the prophylactic use of antiretroviral drugs and treatment adherence in very
young infants. The HIV Prevention Trials Network (HPTN) 046 study (Clinical Trial Registration NCT00074412)
determined the safety and efficacy of an extended regimen of nevirapine suspension in infants born to HIV-1
infected women for the prevention of vertical HIV transmission during breastfeeding. As per protocol, adherence to
nevirapine prophylaxis was measured by maternal verbal reports. In addition, the pharmacy assessed the unused
returned suspension. The aim of this sub-study was to determine the reliability of maternal verbal reports in
measuring adherence to antiretroviral prophylaxis in infants in the first 6 weeks of life and evaluating the unused
returned nevirapine as an alternative method of measuring adherence.
Methods: Maternal verbal reports and pharmacy returns indicative of “missed < 2 doses” were evaluated against a
plasma nevirapine concentration of >100 ng/ml in a subgroup of infants at 2, 5 and 6 weeks of age. Plasma
nevirapine concentration of >100 ng/ml was used as a marker of adherence (10 times the in vitro IC50 against HIV).
Results: Adherence was 87.7% (maternal verbal report) and 71.3% (unused returned medication), as compared to
85.6% by plasma nevirapine concentration. Evaluated against plasma nevirapine concentration <100 ng/ml, the
sensitivity and specificity of maternal verbal reports to detect a missed dose in the last 3 days were 75% and 78%
(p = 0.03) respectively. Overall, among infants who were classified as adherent based on missed doses by maternal
verbal reports and unused returned medication, 88.4% and 87.4% of infants attained a nevirapine concentration
above 100 ng/ml respectively.
Conclusion: Maternal verbal reports are a reliable measure of adherence to infant antiretroviral prophylaxis in the
first 6 weeks of life and could be useful in assessing adherence to antiretroviral treatment in infants younger than 6
weeks. In the absence of resources or expertise to determine plasma drug concentration, we would recommend
random assessments of unused returned medication.
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An estimated 2.3 million people were newly infected
with HIV globally in 2012, of which 260 000 were chil-
dren [1]. The infection was averted in more than 670
000 children from 2009 to 2012 due to the accessibility
of services to prevent mother-to-child transmission [2]
which includes the provision of antiretroviral (ARV)
drugs that are taken by the mother during pregnancy
and delivery and her newborn infant [3].
The number of women and infants that have been re-
ceiving ARV drugs for this purpose has been steadily in-
creasing [4]. An estimated 88% of HIV positive pregnant
women and 56% of HIV exposed infants received ARV
prophylaxis in 2009 alone in South Africa [5]. Early studies
have demonstrated that infant ARV prophylaxis in the first
6 weeks of life could significantly reduce risk of intrapar-
tum or early breastfeeding transmission of HIV [6]. Con-
sequently, evidence based prevention of mother-to-child
transmission (PMTCT) guidelines currently recommend
that nevirapine suspension must be given to all HIV-
exposed infants at birth and for 6 weeks thereafter as
post-exposure prophylaxis for intrapartum and early
breastfeeding transmission, irrespective of feeding prac-
tice or maternal ARV treatment options [7-9].
Adherence to a PMTCT regimen undoubtedly contrib-
utes to its efficacy and hence adherence would be im-
perative to ensure that the target of eliminating new
pediatric HIV infections by 2015 is met [10,11]. Adher-
ence is defined as the extent to which prescribed medi-
cation is taken by patients and is measured by direct and
indirect methods [12]. Direct methods include biological
assays of an active drug in the blood or body fluids and
directly observed therapy (DOT). Indirect measures in-
clude pill counts, Medication Event Monitoring System
(MEMS), pharmacy refills and verbal reports by care-
givers, patients and physicians [13-16]. Each method has
its advantages and disadvantages [17].
Adherence and various measures of adherence are well
documented for the adult population in both low to
middle income and high income countries [18-21]. How-
ever studies on pediatric adherence are limited [14] par-
ticularly the prophylactic use of ARV drugs.
The HPTN046 prospective cohort study (Clinical Trial
Registration NCT00074412) was conducted from June
2008 to March 2010 to determine the safety and efficacy
of an extended regimen of nevirapine in infants born to
HIV-1 infected women for the prevention of vertical
HIV transmission during breastfeeding [8]. In this clin-
ical trial, adherence to nevirapine prophylaxis in infants
was assessed by maternal verbal reports. In this sub-
study we evaluated two indirect measures (maternal ver-
bal reports and unused returned nevirapine medication)
against a direct measure (plasma nevirapine concen-
tration) of adherence in these HIV exposed infantsreceiving daily nevirapine prophylaxis for the first 6 weeks
of life. The overall aim of this evaluation was to ascertain
the reliability of maternal verbal reports and weight mea-
surements of unused returned nevirapine suspension as
an alternative method of measuring adherence.
Methods
Study design, setting and population
This was a retrospective cohort study. Data was retrieved
from the HPTN046 study [8]. This study was conducted
at the Umlazi Clinical Research site located on the
grounds of the Prince Mshiyeni Memorial Hospital
(PMMH) in Umlazi Township. HIV exposed breastfed in-
fants enrolled in the HPTN046 study received nevirapine
suspension (10 mg/ml) for the first 6 weeks of life, and at
6 weeks eligible infants who remained HIV negative were
randomized to receive either an extended regimen of nevi-
rapine or placebo until 6 months of age or until cessation
of breastfeeding, whichever was earliest. Study visits in the
first 6 weeks of life after enrolment (day 3-7 after birth)
were scheduled for 2, 5 and 6 weeks. The dose at enrol-
ment began at 0. 6 ml (6 mg) daily until the 2 week visit at
which point the dose increased to 1. 5 ml (15 mg) given as
a daily dose until the 5 week visit. At this visit, the dose
was then increased to 1. 8 ml (18 mg) daily until day 42
(birth = day 0). Participants who were on study drug
“hold” for safety evaluations were excluded from the
analysis.
The HPTN046 study was approved by the University
of Kwazulu-Natal Ethics Committee (T190/03) and the
Medicines Control Council. Mothers provided written
informed consent at entry into the HPTN046 study. At
each visit in the main study, participants were clinically
examined, blood specimens drawn for laboratory investi-
gations and storage for further research. This sub-study
was a retrospective cohort data analysis in which data
was obtained from the HPTN 046 study. It was ap-
proved by the University of Kwazulu-Natal Ethics Com-
mittee and the HPTN046 study team.
Measurement of adherence by maternal verbal reports
Information regarding infant adherence was obtained
from mothers using a structured questionnaire. Questions
included whether infants missed doses since the previous
visit, the number of days missed and the reason for missed
doses. Other information obtained included maternal
socio-demographic characteristics. The relevant data for
this sub-study were extracted from the main electronic
database at three different time points, at the 2 week, 5
week and 6 week visit for this study. Participants who
reported missing two or more doses were classified
as non-adherent. The association between demographic
characteristics and missed doses reported by mothers was
determined for the longest period (2-5 week visit).
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infant and they also reported on whether the infants
missed 2 or more days in a row in the period between
visits. Responses to both questions were utilized in the as-
sessment of adherence.
Measurement of adherence by assessment of unused
returned Nevirapine
Nevirapine suspension was dispensed to mothers at each
visit. Women received instructions for administration of
the suspension to their infants. These instructions were
also printed on the labels attached to the bottles of medica-
tion. Adherence counseling was performed after each dis-
pensing. The number of bottles dispensed varied at each
visit according to the HPTN046 protocol. Used bottles
containing remaining nevirapine suspension were returned
by participants at the next visit. Each bottle was weighed
independently by pharmacists. Six full bottles were weighed
and an average was calculated to obtain an average weight
of 29.4 g for a full bottle of nevirapine suspension. The
number of missed doses was calculated by dividing the dif-
ference between the volume used and volume that should
have been used by the daily dosage. This figure was there-
after adjusted for potential spillage and adhesion of suspen-
sion to the syringe walls and tip by adding one dose to the
measured weight of the suspension in the bottle.
Plasma Nevirapine concentration
Nevirapine concentrations were determined in stored
plasma samples of adequate volumes in a subgroup of
participants at the 5 and 6 week visits for the purpose of
comparing maternal verbal reports to weighed returned
medication. Concentrations were determined by LC-MS/
MS (Division of Clinical Pharmacology, University of
Cape Town). The assay was validated according to FDA
and EMA guidelines. Plasma samples were extracted
and chromatographic separation was achieved on a Luna
5 μm PFP (2), 100 A, 50 mm × 2 mm analytical column.
An AB Sciex API 4000 mass spectrometer was operated
at unit resolution in the multiple reaction monitoring
(MRM) mode, monitoring the transition of the proton-
ated molecular ions at m/z 266.9 to the product ions at
m/z 198.2 for Nevirapine, and monitoring the transition
of the protonated molecular ions at m/z 270.1 to the
product ions m/z 229.1 for the stable isotope labeled ne-
virapine internal standard. The calibration curve fitted a
quadratic (weighted by 1/concentration2) regression over
the ranges 0.0195 – 20.0 μg/ml. Nevirapine concentra-
tion above 100 ng/ml was used as a marker for adher-
ence (10 times the in vitro IC50 against HIV) [22,23].
Statistical analysis
Categorical variables were summarized as percentages.
Frequency distributions of continuous variables did notmeet the Shapiro-Wilk W test for normal data therefore
medians and inter-quartile ranges (IQR) were used as
summary measures. These variables were also dichoto-
mized using commonly accepted cut-points. Subgroups
were compared using Chi Square tests or Fisher’s exact
test for categorical variables and Odds Ratio and 95%
confidence interval reported. Independent associations
with missed dose reporting were examined using a step-
wise logistic regression model which includes all vari-
ables. Two sided P < 0.05 was considered statistically
significant. All analyses were performed using EPI-info
(version 3.4.3) and Stata (version 12).
Results
Study population characteristics
A total number of 225 mother-infants pairs were in-
cluded in this sub-study analysis. Maternal ages ranged
from 18 years to 42 years with a median age of 25.7
years (IQR 22.5-29.7) The majority of women (90.7%)
were single and not living with a partner and first preg-
nancies were reported in one in four women. Literacy
levels amongst the women were relatively high with
93.3% achieving grade 7. Almost half of the women
(45.5%) were in an advanced stage of HIV (CD4 ≤ 350 cells/
mm3) and women receiving triple ARV’s as treatment had
a CD4 count of less than 200 cells/mm3 [24]. Two thirds
of the women (64.9%) had normal vaginal deliveries and
79 (35.1%) had caesarean sections. The mean birth weight
was 3.1 (range 2-4.3) and 11.6% of infants (26/225)
weighed under 2.5 kg.
Maternal verbal reports
Adherence was assessed at the 2 week (n = 223), 5
week (n = 207) and 6 week visits (n = 210). Three
(1.3%), twelve (5.8%) and two (1.0%) women reported
that 2 or more doses were missed at the 2, 5 and 6
week visits respectively. Adherence was calculated as
98.7% (220/223), 94.2% (195/207) and 99.0% (208/210)
at 2, 5 and 6 week visits respectively (Figure 1). Rea-
sons for missed doses amongst the 17 women that re-
ported 2 or more missed doses included difficulties in
drawing medication from the bottle (11.8%), misunder-
standing (mothers stopped dosing the infant as they
were not aware that they could re-use syringes pro-
vided) (11.8%), mother was ill or hospitalized (17.6%),
mother forgot (5.9%), missed visit (5.9%), mother
stopped breastfeeding (29.4%), mother thought that the
study drug was expired (5.9%), disclosure issue (5.9%)
and lack of support (5.9%). Adherence in the subgroup
that had plasma nevirapine concentrations determined
at the 5 week (n = 49) and 6 week visits (n = 24) was
79.6% (39/49) and 95.8% (23/24) respectively. Average
adherence for this subgroup was 87.7% with maternal
verbal report (5 and 6 week visits).
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Figure 1 Adherence based on missing ≥ 2 doses: Maternal verbal report (MVR), Unused Returned Nevirapine (NVP) and > 100 ng/ml
plasma NVP concentration.
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maternal verbal report missed doses at the 5 week visit
In general, younger women who were single and were
primigravida more often reported a missed dose than
older women with a partner and who were multiparous
however these differences were not statistically signifi-
cant. More women that were 25 years and younger re-
ported a missed dose, 18% (21/116) versus 15% (15/102)
for women above 25 years of age (OR 1.3; 95% CI 0.6-
3.0). Single women were also more likely to report
missed doses, 18% versus 5% in married/living with a
partner (OR 4.1; 95% CI 0.5 – 31) and (OR 1.3; 95% CI
0.5 – 2.9). More women pregnant for the first time re-
ported a missed dose 19% (9/48) compared to that of a
multiparous woman, 16% (24/154) OR: 1.3 (95% CI
0.5-2.9). Women receiving an ARV regimen either re-
ceived medication for PMTCT (1), a triple ARV regimen
(2) or medication for PMTCT and a triple ARV regimen
(3). There were also mothers that received no ARV medi-
cation (0) (Table 1). Nevirapine concentrations were deter-
mined in 8 infants whose mothers were on a triple ARV
regimen containing nevirapine. The average concentration
amongst these women was 1709 ng/ml. The average con-
centration amongst those infants whose mothers were not
exposed to nevirapine was 1702 ng/ml hence exposure to
maternal nevirapine did not alter the plasma concentra-
tions in the infants. After controlling for possible con-
founding variables such as age, marital status, education,
HIV clinical stage, ARV regimen and infant birth weight, a
multivariate logistic regression showed no variables inde-
pendently related to reporting of missed doses.
Adherence based on unused returned Nevirapine
The number of missed doses was calculated at the 2
week (n = 225), 5 week (n = 196) and 6 week (n = 191)visits. Seven (3.1%), twenty three (11.7%) and six (3.1%)
infants missed 2 or more than doses at the 2, 5 and 6
week visits respectively. Adherence based on returned
nevirapine at the 2, 5 and 6 week visits was estimated as
96.9% (218/225), 88.3% (173/196) and 96.9% (185/191)
respectively (Figure 1). Adherence in the subgroup that
had plasma nevirapine concentrations determined at the
5 week (n = 49) and 6 week (n = 24) visits was 59.2%
(29/49) and 83.3% (20/24) respectively. Average adher-
ence for unused returned nevirapine was 71.3% for this
subgroup (5 and 6 week visits).
Plasma nevirapine concentration
The median nevirapine concentrations were 1620 ng/ml
(IQR 1000-2220 ng/ml) and 1380 ng/ml (IQR 448-2835
ng/ml) at the 5 week (n = 49) and 6 week (n = 24) visits
respectively. 83.7% (41/49) (95%CI 70.3-92.7) and 87.5%
(21/24) (95% CI 67.6-97.3) of the infants had a plasma
nevirapine concentration of more than 100 ng/ml at
5 wk and 6 wk respectively (Figure 1). Average adher-
ence determined by nevirapine concentration was 85.6%
(5 and 6 week visits).
Agreement between plasma nevirapine concentration,
maternal verbal reports and unused returned nevirapine
in identifying missed doses
The sensitivity of maternal verbal report in the last 3
days and unused returned nevirapine to detect missed
doses was exactly the same at the 5 week visit (75% [95%
CI 35-97]) p = 0.9. The specificity was 78% [95% CI 62-89]
at the 5 week visit for maternal verbal report and was sig-
nificantly higher than nevirapine returns at this visit (42%
[95% CI 26-58) (p =0.002) (Table 2). The sensitivity for
unused returned nevirapine to detect missed doses at the
6 week visit was 100% however there were only 3
Table 1 Maternal and infant characteristics in association
with maternal verbal reports (MVR) missed dose at the
5 week visit
MVR MISSED DOSE
Yes
(n = 36)
No
(n = 182)
n (%) n (%) OR 95% CI P value
Age
≤25 years 21 (18) 95 (82) 1.3 (0.6 - 3)
>25 years 15 (15) 87 (85) ref 0.6
Marital status (n, %)
Single 35 (18) 163 (82) 4.1 (0.5 – 31) 0.2
Married 1 (5) 19 (95) ref
Education
≤ Grade 7 1 (7) 13 (93) ref
> Grade 7 35 (17) 169 (83) 2.7 (0.3 – 21.3) 0.3
Parity (n, %)
Primigravida 9 (19) 39 (81) 1.3 (0.5 – 2.9) 0.6
Multiparous 24 (16) 130 (84) ref
HIV clinical stage and ARV
CD4 ≤ 350 (n%) 17 (17) 81 (83) 1.1 (0.5-2.3) 0.8
CD4 > 350 (n%) 19 (16) 101 (84) ref
WHO Clinical stage (n, %)
1 33 (16) 170 (84) 1.2 (0.1 - 10) 0.9
2 or 3 1 (14) 6 (86) ref
Receiving ARV regimen (n,%)
0, 1 29 (18) 136 (82) 1.4 (0.6 - 3.4) 0.5
2, 3 7 (13) 46 (87) ref
Mode of delivery (n, %)
Normal 25 (17) 118 (83) 1.2 (0.6 – 3.0) 0.6
C/S 11 (15) 64 (85) ref
Birth weight (n, %)
2.0 - 2.5 kg 4 (15) 22 (75) ref
>2.5 kg 32 (17) 160 (83) 1.1 1.1 (0.4 - 3) 0.9
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100 ng/ml. Again, the specificity was higher (70% [95%
CI 46-88]) for the maternal verbal report than the un-
used returned nevirapine (38% [95% CI 18-62]) at the 6
week visit.Table 2 Agreement between nevirapine concentration and m
nevirapine (NVP) in identifying missed doses at the 5 week v
Adherence measure Sensitivity Specificity
MVR n (%) 95% CI 6/8 (75%) (35; 97) 32/41 (78%)
unused returned NVP n (%) 95% CI 6/8 (75%) (35; 97) 17/41 (42%)
*P-value represents the comparison between maternal verbal reports/unused returnRelationship between maternal verbal reports, unused
returned nevirapine and nevirapine concentration in
adherent and non-adherent patients
At the 5 week visit, 89.7% of infants whose mothers re-
ported adherence (missing one dose or not missing any
doses) had a plasma nevirapine concentration of greater
than 100 ng/ml. The same percentage (89.7%) of infants
that were categorized adherent as calculated from the
unused returned nevirapine had a concentration of
greater than 100 ng/ml. At the 6 week visit, 87% of in-
fants whose mothers reported adherence had a plasma
nevirapine concentration of greater than 100 ng/ml and
85% as calculated on the unused returned nevirapine
(Table 3).
For those infants whose mothers reported missing 2 or
more doses at the 5 week visit, 60% had a plasma nevira-
pine concentration of greater than 100 ng/ml. 75% of
those that missed 2 or more doses according to the un-
used returned nevirapine had a plasma nevirapine con-
centration of greater than 100 ng/ml. At the 6 week
visit, all infants that missed 2 or more doses as per ma-
ternal verbal report and unused returned nevirapine had
a plasma concentration of greater than 100 ng/ml.
Correlation between maternal verbal reports and unused
returned nevirapine at the longest visit
A comparison of the percentages during the longest
period (2-5 week) reveals that there is no significant dif-
ference in the doses missed for nevirapine returns
(21.3%) (44/207) and maternal verbal reports (15.5%)
(32/207) (p = 0.1). This indicates good agreement be-
tween the two measures (Mcnemars chi2 (1) = 2.67,
Prob > chi2 = 0.1025).
Discussion
In this study, adherence to antiretroviral prophylaxis in
HIV exposed infants in the first 6 weeks of life was
assessed using two indirect methods (verbal reports and
unused returned medication) in association with a direct
method (plasma concentration of medication). Prophy-
lactic adherence determined by maternal verbal reports
exceeded 90% at all clinic visits in the 6 week period.
Adherence as measured by unused returned medication
was marginally lower at short visit intervals but signifi-
cantly lower when medication was returned after a long
visit interval.aternal verbal reports (MVR) and unused returned
isit
PPV NPV P-value *
(62; 89) 6/15 (40%) (16; 68) 32/34 (94%) (80; 99) 0,03
(26; 58) 6/30 (20%) (8; 39) 17/19 (89%) (67; 99) <0.001
ed nevirapine and NVP concentration.
Table 3 Relationship between maternal verbal report (MVR), unused returned nevirapine (NVP) and NVP concentration
in adherent patients (missed < 2 doses)
Visit Infants classified as adherent by
MVR (n)
Infants classified as adherent by MVR and
have > [100 ng/ml] n (%)
Infants classified as adherent by MVR and
have < [100 ng/ml] n (%)
5 week 39 35 (89.7%) 4 (10.3%)
6 week 23 20 (87.0%) 3 (13.0%)
Infants classified as adherent by
unused NVP (n)
Infants classified as adherent by unused NVP
and have > [100 ng/ml] n (%)
Infants classified as adherent by unused NVP
and have < [100 ng/ml] n (%)
5 week 29 26 (89.7%) 3 (10.3%)
6 week 20 17 (85.0%) 3 (15.0%)
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ence to medication [25] among adults and children and
this measure of adherence has been previously evaluated
in treatment studies. There are no known evaluation
studies of this measure for use in assessing adherence to
a prophylactic regimen in children. Previous studies have
shown that adherence reported by caregivers is an in-
flated figure in comparison with other measures in HIV
infected children [26]. This has also found to be the case
in the adult population with self-reported adherence
[27]. In our study, adherence as per maternal verbal re-
ports was more comparable to adherence determined by
the direct method of plasma nevirapine concentration in
the subgroup of participants than unused returned nevi-
rapine. The subgroup was the small number of partici-
pants for who adequate volumes of plasma was available
to determine nevirapine concentrations. A difference can
be noted in adherence based on maternal verbal report in
the nevirapine level subgroup (79.6%) in comparison to
the overall group (94.2%) at the 5 week visit. This is be-
cause the subgroup included almost all (10) of the patients
that were non-adherent in the general group (12). Agree-
ment between plasma nevirapine concentration and ma-
ternal verbal reports was found to be slightly better than
the agreement between plasma nevirapine concentration
and unused returned nevirapine at the visit after the lon-
gest gap. The specificity for the unused returned nevira-
pine was much lower than the maternal verbal reports due
to the fact that the unused returned nevirapine was con-
founded by the longer period. This was one of the limita-
tions of the study. It was not possible to investigate if the
last few doses were missed when calculating adherence
using weights of unused returned nevirapine, whereas in-
formation that mothers provided included the last 3 doses
that the infant had taken and this could therefore be used
in determining agreement between plasma nevirapine
concentration and maternal verbal reports. This is the case
because plasma drug concentration is a reflection of the
last few doses that a patient has taken [28]. Factors that
affect plasma drug concentration levels [26] include inter-
patient variation and the timing of drawing a blood sample
in relation to the last dose taken [28]. It has previouslybeen shown that the decay in plasma concentrations of
nevirapine within dosage intervals is fairly small therefore
randomly taken samples are adequate [29,30]. Due to the
fact that nevirapine has a long elimination half-life, great
intra-individual variations in plasma concentration was
not expected [29,30]. Nevirapine is metabolised primarily
by cytochrome P450 CYP3A4 and CYP2B6 [31]. Adult
studies have reported that the CYP 2B6 516G→T poly-
morphism is associated with elevated nevirapine plasma
concentrations in HIV infected patients [32-34]. Similarly,
studies conducted in infants have reported that those in-
fants with the CYP2B6 516 TT (homozygous mutants)
genotype had a decreased oral clearance of nevirapine in
comparison to those with 516GT (heterozygous) and 516
GG (wildtype) genotypes [35,36]. It was also previously re-
ported that the CYP2D6 enzymes play a role in metabol-
ism in HIV infected children [37]. It is possible that these
polymorphisms influence nevirapine concentrations in the
infants in this study, however this was not assessed.
It is not clear from previous research exactly how
many doses can be missed consecutively in the pediatric
population for the concentration to fall below the re-
quired level (100 ng/ml -10 times the in vitro 50% con-
centration against HIV-1). It was previously found in a
study where trough nevirapine levels were determined,
that in order to maintain a therapeutic target of 100 ng/ml
in 100% of participants, infants had to receive a once daily
dose. However a twice weekly dose given on the first and
fourth days of each week also maintained a therapeutic
target of 100 ng/ml in 62 of 65 samples (95.4%) [38]. It
can be deduced from this study and our sub-study that in-
fants who miss two to three consecutive doses can still ob-
tain the nevirapine concentration of 100 ng/ml, therefore
they would need to receive at least twice weekly doses
given a maximum of 72 hours apart.
In our study, the maternal verbal report had given us
a better indication of adherence in comparison to the
measure of unused returned nevirapine. It was entirely
the caregiver’s responsibility to ensure good adherence
in this study as infants assessed were between the ages
of 3 days and 6 weeks of age. Mothers (caregivers) were
required to report adherence. Other studies that
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call [13,26,39-41] 4 day recall [25] and 24 hour recall
methods [16]. In comparison, our study required mothers
to also report on doses missed since the last visit which
could have been 3 to 26 days earlier. Caregiver reports
have been found to be a reliable measure in the assess-
ment of adherence in some studies [16,42].
The direct method of determining plasma nevirapine
concentrations has been used previously to detect non
adherence [43]. In our study, it was used as a gold stand-
ard, for the purpose of assessing other measures of ad-
herence. However the limitation of this study is that
plasma nevirapine concentrations were determined in a
subgroup of participants.
Caregiver reports are utilized to a greater extent than
other adherence measures in routine practice. It has previ-
ously been reported that using multiple measures of adher-
ence is more beneficial than using a single measure [44].Conclusion
We have concluded that maternal verbal reports are a reli-
able measure of adherence to infant antiretroviral prophy-
laxis in the first 6 weeks of life and could be useful in
assessing adherence to antiretroviral treatment in infants
younger than 6 weeks. In the absence of resources or ex-
pertise to determine plasma drug concentration, we would
recommend random assessments of unused returned
medication.
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